{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-031981","form_type":"8-K","ticker":"RVPH","cik":"0001742927","company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","filed_at":"2023-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.285050+00:00","generated_at":"2026-06-08T03:51:18.585200+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"high","headline":"Reviva shareholders elect all five director nominees and ratify Moss Adams as auditor at 2023 annual meeting","bullets":["All five director nominees elected: Laxminarayan Bhat, Parag Saxena, Richard Margolin, Purav Patel, Les Funtleyder.","Votes for director nominees ranged from 7,991,179 to 8,713,962; broker non-votes of 5,873,081 on each.","Ratification of Moss Adams LLP as auditor approved: 14,574,768 for, 11,880 against, 9,917 abstentions.","Meeting held November 13, 2023; results filed under Item 5.07."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-031981","json":"https://secwatch.observer/filing/0001437749-23-031981.json","markdown":"https://secwatch.observer/filing/0001437749-23-031981.md","text":"https://secwatch.observer/filing/0001437749-23-031981.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1742927/000143774923031981/0001437749-23-031981-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1742927/000143774923031981/rvph20231109_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T03:51:18.585200+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1dfd94107a7970d45935795dc1a87c096dfa31cd","claim":"REVIVA PHARMACEUTICALS HOLDINGS, INC. shareholders approved Ratification of the appointment of Moss Adams LLP as the Company’s independent registered public accounting firm for the Company’s fiscal year ending December 31, 2023 at the 2023-11-13 meeting.","evidence_excerpt":"2. The proposal to ratify the appointment of Moss Adams LLP as the Company’s independent registered public accounting firm for the Company’s fiscal year ending December 31, 2023 was approved based upon the following votes: Votes For Votes Against Abstentions Broker Non-Votes 14,574,768 11,880 9,917 0","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1742927/000143774923031981/0001437749-23-031981-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-11-13"}],"fact_type":"shareholder_vote"},{"claim_id":"680cbb04c03e17d3da4f7a30a58ba898e3eb819c","claim":"REVIVA PHARMACEUTICALS HOLDINGS, INC. shareholders approved Election of each of Laxminarayan Bhat, Parag Saxena, Richard Margolin, Purav Patel and Les Funtleyder as directors at the 2023-11-13 meeting.","evidence_excerpt":"1. The election of each of Laxminarayan Bhat, Parag Saxena, Richard Margolin, Purav Patel and Les Funtleyder as directors to hold office for a term of one year, until their successor is duly elected and qualified or they are otherwise unable to complete their term. The votes were cast for this matter as follows: Votes Broker Non- Nominees Votes For Withheld Votes Laxminarayan Bhat 8,713,818 9,666 5,873,081 Parag Saxena 7,991,179 732,305 5,873,081 Richard Margolin 8,713,949 9,535 5,873,081 Purav Patel 8,713,807 9,677 5,873,081 Les Funtleyder 8,713,962 9,522 5,873,081","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1742927/000143774923031981/0001437749-23-031981-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-11-13"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}